Breaking News

Inactivated, Adjuvanted COVID-19 Vaccine Candidate Compares Very Well

October 18, 2021 • 8:32 pm CDT
(Precision Vaccinations News)

France-based Valneva SE announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

The pivotal Phase 3, Cov-Compare trial, recruited 4,012 participants aged 18 years and older across 26 trial sites in the United Kingdom.

The trial met its co-primary endpoints: VLA2001 demonstrated superiority against AZD1222 (ChAdOx1-S) in terms of geometric mean titer for neutralization antibodies, as well as non-inferiority in terms of seroconversion rates at two weeks after the second vaccination (i.e., Day 43) in adults aged 30 years and older.

T-cell responses analyzed in a sub-set of participants showed that VLA2001 induced broad antigen-specific IFN-gamma producing T-cells reactive against the S- (74.3%), N- (45.9%), and M- (20.3%) protein.

No unsolicited treatment-related serious adverse events (SAE) have been reported.

Less than 1% reported an adverse event of special interest in both treatment groups. In addition, participants in the younger age group vaccinated with VLA2001 showed an overall safety profile comparable to the older age group.

The complete absence of any severe COVID-19 cases may suggest that both vaccines used in the study prevented severe COVID-19 caused by the circulating variant(s) (predominantly Delta).

Adam Finn, Professor of Paediatrics, University of Bristol, Trial Chief Investigator, said in a press statement issued on October 18, 2021, "The low levels of reactogenicity and high functional antibody responses alongside broad T-cell responses seen with this adjuvanted inactivated whole virus vaccine are both impressive and extremely encouraging."

"This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe, and North America, and these results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic."

In addition, Valneva has completed the recruitment of volunteers in New Zealand into its VLA2001-304 trial and expects topline data in early 2022. Valneva has also announced the start of recruitment of adolescents as an expansion of the Cov-Compare trial.

The Company is preparing for trials in children (5-12 years of age) and a Valneva sponsored booster trial to evaluate VLA2001's booster performance for people in need of a booster.

Valneva commenced rolling submission for initial approval with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and is preparing to commence rolling submission for conditional approval with the European Medicines Agency.

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Medical Review by

Our Trust Standards: Medical Advisory Committee

Share